Kymera Therapeutics (KYMR) Operating Expenses (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Operating Expenses of $118.5 million for Q1 2026, up 22.78% year-over-year from $96.5 million in Q1 2025, and up 17.62% quarter-over-quarter from $100.8 million in Q4 2025.
Kymera Therapeutics (KYMR) Operating Expenses (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Operating Expenses for 8 consecutive years, with $118.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 22.78% year-over-year to $118.5 million; the TTM figure through Mar 2026 stood at $410.6 million (up 21.8% YoY), while the FY2025 annual figure was $388.6 million, up 25.88% from the prior year.
- Operating Expenses rose to $118.5 million in Q1 2026 per KYMR's latest filing, from $100.8 million in the prior quarter.
- Across five years, Operating Expenses topped out at $118.5 million in Q1 2026 and bottomed at $46.6 million in Q1 2022.
- Historically, Operating Expenses has averaged $74.6 million across 5 years, with a median of $68.1 million in 2024.
- On a YoY basis, Operating Expenses climbed as much as 46.07% in 2022 and fell as far as 11.15% in 2022.
- Kymera Therapeutics' Operating Expenses stood at $54.8 million in 2022, then grew by 22.69% to $67.2 million in 2023, then jumped by 31.18% to $88.1 million in 2024, then climbed by 14.31% to $100.8 million in 2025, then grew by 17.62% to $118.5 million in 2026.
- Business Quant data shows KYMR's Operating Expenses at $118.5 million in Q1 2026, $100.8 million in Q4 2025, and $95.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 140.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 140.61 Mn |
| Mar 31, 2026 | 118.52 Mn |
| Dec 31, 2025 | 100.77 Mn |
| Sep 30, 2025 | 95.29 Mn |
| Jun 30, 2025 | 96.03 Mn |
| Mar 31, 2025 | 96.53 Mn |
| Dec 31, 2024 | 88.15 Mn |
| Sep 30, 2024 | 75.87 Mn |
| Jun 30, 2024 | 76.58 Mn |
| Mar 31, 2024 | 68.12 Mn |
| Dec 31, 2023 | 67.20 Mn |
| Sep 30, 2023 | 62.24 Mn |
| Jun 30, 2023 | 59.90 Mn |
| Mar 31, 2023 | 54.79 Mn |
| Dec 31, 2022 | 54.77 Mn |
| Sep 30, 2022 | 54.43 Mn |
| Jun 30, 2022 | 52.32 Mn |
| Mar 31, 2022 | 46.56 Mn |
| Dec 31, 2021 | 49.27 Mn |
| Sep 30, 2021 | 48.97 Mn |